TCRT:NASDAQAlaunos Therapeutics, Inc. Analysis

Alaunos Therapeutics (TCRT) is trading at $1.88, just above its identified support of $1.81 and well below its 20‑day ($2.01), 50‑day ($2.21) and 200‑day ($2.82) simple moving averages, indicating a sustained bearish price trend. Technical momentum is weak, with a 14‑day RSI of 35 suggesting limited upside and a MACD histogram turning negative, while volume has been decreasing and 30‑day volatility spikes above 56%, underscoring price instability. Fundamentally, the company reports zero revenue growth, negative operating margins (‑1382%), and a trailing EPS of –$2.12, resulting in a nonsensical PE ratio and a price‑to‑sales multiple above 1500, which together point to severe valuation concerns.
The only positive catalyst is a recent pre‑clinical study (ALN1003) showing reduced liver weight in a diet‑induced obesity mouse model, but this data remains early‑stage and does not offset the broader financial and technical weaknesses.